Showing results (481-490 of 566) with videos related to

Sort By:
Pageof 57
Advances in Experimental Medicine and Biology|September 29, 1999
Apoptosis. Molecules and mechanismsM Konopleva, S Zhao, Z Xie, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC)S Kempin, Z Arlin, E Berman, et al.
Blood|August 9, 2001
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemiaG G Wulf, R Y Wang, I Kuehnle, et al.
Leukemia|June 13, 2008
The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AMLK Kojima, M Shimanuki, M Shikami, et al.
Leukemia|January 18, 2008
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathwayW Zhang, M Konopleva, V R Ruvolo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2000
BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemiaS M Kornblau, H T Vu, P Ruvolo, et al.
Blood|April 9, 1999
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndromeE H Estey, P F Thall, S Pierce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factorE Estey, P Thall, M Andreeff, et al.
Blood|February 15, 1997
Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemiaA Choudhury, J L Gajewski, J C Liang, et al.
British Journal of Haematology|February 5, 1998
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemiaA Younes, V Snell, U Consoli, et al.
Pageof 57